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FIGURE 1 Yearly Rate of Thromboembolic Events in AF Patients
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>1 in males, >2 in females. Ao ¼ aortic; AF ¼ atrial ﬁbrillation; NVAF ¼ nonvalvular atrial
ﬁbrillation; VKA ¼ vitamin K antagonist.
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2015;36:1822–30.Effects of P-Selectin
Antagonist Inclacumab
in Patients Undergoing
Coronary Artery Bypass
Graft Surgery
SELECT-CABG TrialDespite unprecedented advances over the last few
decades, saphenous vein graft (SVG) failure remains a
major concern following coronary artery bypass graft
(CABG) surgery (1), and since contemporary treatment
options are limited in these patients, there is an
unmet need for novel therapeutic concepts. Early
evidence to support the adhesion molecule P-selectin
as a potential therapeutic target was provided by
different animal models of vascular inﬂammation
(2,3), as well as phase I clinical studies (4). The recent
SELECT-ACS (Effects of the P-Selectin Antagonist
Inclacumab on Myocardial Damage After Percuta-
neous Coronary Intervention for Non–ST-Segment
Elevation Myocardial Infarction) trial then demon-
strated the efﬁcacy of inclacumab, a human
monoclonal antibody directed against P-selectin, in
reducing myocardial damage following percuta-
neous coronary intervention in patients presenting
with acute coronary syndromes (5). The SELECT-
CABG (Effects of P-Selectin Antagonist Inclacumab
in Patients Undergoing Coronary Artery Bypass
Graft Surgery) trial was therefore designed to
assess the effects of inclacumab on SVG disease
assessed by quantitative coronary angiography 1
year after CABG surgery.
Between December 2010 and May 2012, this pro-
spective, randomized, multicenter, double-blind,
placebo-controlled trial enrolled patients undergoing
CABG surgery (with the use of $1 SVG) at 38 centers in
Canada and the United States. Of 394 patients
TABLE 1 Patient Characteristics, Angiographic Efﬁcacy Measures, and Clinical Outcomes
Per-Protocol Population
Placebo
(n ¼ 144)
Inclacumab
(n ¼ 148)
All
(n ¼ 292)
Patient characteristics
Age, yrs 62.8  8.2 62.1  9.2 62.4  8.7
Male 129 (89.6) 132 (89.2) 261 (89.4)
Primary efﬁcacy measure at 1 year
Patients with diameter stenosis >50% of at least 1 SVG 38 (26.4) 33 (22.3) 71 (24.3)
Adjusted odds ratio (95% conﬁdence interval) 0.80 (0.47–1.38)
p value 0.43
Secondary efﬁcacy measures at 1 year
SVG with diameter stenosis >50% 49 (15.5) 47 (14.0) 96 (14.7)
Adjusted odds ratio (95% conﬁdence interval) 0.89 (0.53–1.49)
p value 0.65
Patients with diameter stenosis >75% of at least 1 SVG 34 (23.6) 31 (20.9) 65 (22.3)
Adjusted odds ratio (95% conﬁdence interval) 0.86 (0.49–1.50)
p value 0.59
SVG with diameter stenosis >75% 43 (13.6) 43 (12.8) 86 (13.2)
Adjusted odds ratio (95% conﬁdence interval) 0.93 (0.54–1.60)
p value 0.79
Minimal lumen diameter in SVG, adjusted mean, mm 2.24 2.10
95% conﬁdence interval 1.92–2.56 1.78–2.41
p value 0.32
Major adverse cardiovascular events at 1 year 20 (13.9) 21 (14.2) 41 (14.0)
Adjusted odds ratio (95% conﬁdence interval) 1.05 (0.54–2.04)
p value 0.88
All-cause and cardiovascular death 0 (0) 0 (0) 0 (0)
Nonfatal myocardial infarction 4 (2.8) 5 (3.4) 9 (3.1)
Stroke 1 (0.7) 2 (1.4) 3 (1.0)
At least 1 revascularization procedure 15 (10.4) 12 (8.1) 27 (9.2)
Hospitalization for heart failure 2 (1.4) 4 (2.7) 6 (2.1)
Hospitalization for acute coronary syndrome >24 h 0 (0) 1 (0.7) 1 (0.3)
Values are mean  SD or n (%), unless otherwise indicated.
SVG ¼ saphenous vein graft.
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345screened, 384 were randomized between 4 h and
6 weeks before CABG surgery to receive inclacumab
(20 mg/kg; F. Hoffmann-La Roche, Basel, Switzerland)
or placebo administered at 4-week intervals during a
treatment period of 32 weeks. Quantitative coronary
angiography was performed utilizing the Cardiovas-
cular Measurement System (Medis Medical Imaging
Systems, Leiden, the Netherlands). Plasma soluble
P-selectin was measured utilizing an enzyme-linked
immunosorbent assay (R&D Systems Inc., Minneap-
olis, Minnesota). The institutional review boards
approved the protocols, and all patients provided
written informed consent. Endpoints were compared
using a logistic regression model or analysis of vari-
ance adjusting for on-pump versus off-pump CABG
surgery and endoscopic versus open saphenous vein
harvesting. The proportion of vessels with different
stenosis cutoff values was analyzed using generalized
estimating equation models. For plasma soluble P-selectin levels, differences between groups were
described through placebo-adjusted geometric mean
percent change and compared utilizing repeated-
measures analysis of covariance.
Patient characteristics are summarized in Table 1.
Baseline plasma soluble P-selectin levels (geometric
means) were 29.2 ng/ml (23.7 to 33.7 ng/ml)
and 32.4 ng/ml (27.5 to 41.7 ng/ml) in the placebo
and inclacumab groups. Inclacumab resulted in a
placebo-adjusted geometric mean percent change of
–23.4% (p ¼ 0.006) at 48 h after CABG surgery. In
the 292 patients of the per-protocol population,
26.4% and 22.3% of patients in the placebo and
inclacumab groups had $1 SVG with a diameter
stenosis >50%, the primary efﬁcacy measure
(adjusted odds ratio [OR]: 0.80; 95% conﬁdence
interval [CI]: 0.47 to 1.38; p ¼ 0.43) (Table 1). In the
311 patients of the intention-to-treat population
who received $1 SVG and at least 1 study drug
Letters J A C C V O L . 6 7 , N O . 3 , 2 0 1 6
J A N U A R Y 2 6 , 2 0 1 6 : 3 4 3 – 5 2
346infusion and underwent angiography at 1 year
follow-up, corresponding rates were 28.7% and
21.4%, respectively (adjusted OR: 0.67; 95% CI: 0.40
to 1.13; p ¼ 0.14). Differences between placebo and
inclacumab groups for all pre-speciﬁed secondary
efﬁcacy measures were not statistically signiﬁcant
(Table 1). 13.9% and 14.2% of patients in the placebo
and inclacumab groups had $1 reported major
adverse cardiovascular event (p ¼ 0.88) (Table 1).
There were no apparent inclacumab-induced effects
on bleeding events.
Post hoc analyses showed an interaction between
the plasma soluble P-selectin level at baseline and
the treatment arm on the primary efﬁcacy measure
(p ¼ 0.053). In patients with baseline P-selectin levels
above the median, the primary efﬁcacy measure
tended to be reduced in the inclacumab (12.8%)
as compared to the placebo group (27.8%; adjusted
OR: 0.37; 95% CI: 0.12 to 1.15; p ¼ 0.085), while this
trend was not observed in patients with baseline
levels below the median (27.0% in the inclacumab vs.
19.1% in the placebo group; adjusted OR: 1.69; 95% CI:
0.60 to 4.77; p ¼ 0.33).
This SELECT-CABG study showed that the speciﬁc
anti-P-selectin antibody inclacumab did not exert
signiﬁcant favorable effects on SVG disease progres-
sion. Given these results, it is possible that the
P-selectin pathway plays an overall less important
role in the pathogenesis of venous graft failure
than previously hypothesized. However, a post hoc
analysis suggested that the pre-existing level of
activation of the P-selectin pathway may determine
the response to inclacumab, a ﬁnding that needs to be
evaluated prospectively.Barbara E. Stähli, MD
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Treatment as Default
Strategy for DES-ISRWe read with interest the publication of RIBS
IV (Restenosis Intra-stent of Bare Metal Stents:
Paclitaxel-eluting Balloon vs Everolimus-eluting
Stent) trial by Alfonso et al. (1), questioning the role
of drug-coated balloons (DCB) in the treatment of
drug-eluting stent restenosis (DES-ISR).
The use of DCB and bioresorbable scaffolds not
only reduces vessel occlusion but serves to promote
vascular healing by leaving no permanent implant
within the vessels. To obtain the full beneﬁt of such
treatment, optimal lesion preparation is crucial (2).
When starting a DCB program, a learning curve
is inevitable, addressing factors like handling the
device, geographical mismatch, and knowledge of
